Medsafe Speeds Up Approval Assessments: Stats Show

Associate Health Minister David Seymour highlights that Medsafe is significantly accelerating medicine approvals, completing assessments for innovative, generic, and over-the-counter categories much faster than before. This speed, particularly the rapid clearance of low-risk products like pseudoephedrine, demonstrates how risk-based, bespoke processes can effectively remove barriers to patient access without compromising safety standards. Despite these improvements, Seymour argues that further streamlining is essential to ensure Kiwis receive timely care. He advocates for continuous innovation in regulatory methods, emphasizing that the current system must not unreasonably delay access to life-enhancing treatments. The focus remains on adapting processes to meet public health needs efficiently. This update is relevant to open data because it relies on transparent performance statistics to validate regulatory efficiency. By publicly releasing data that shows measurable improvements in assessment times, Medsafe provides empirical evidence that supports policy changes like the proposed new verification pathway. Such transparency allows stakeholders to trust that data-driven reforms are successfully modernizing pharmaceutical regulation for better public outcomes.

Source: miragenews.com
Published on 2024-11-05

Making Sense of the Numbers: How Transparency Shapes Trust, Justice, and Global Economics »

Open Data

Related news